Blood markers may predict dangerous transplant complication
NCT ID NCT01520623
First seen Mar 07, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflammation affects transplant success and find new targets for treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGRAFTED WITH MYELOABLATIVE CONDITIONING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker Hospital
Paris, 75, France
-
Saint Antoine Hospital
Paris, 75012, France
-
Saint Louis Hospital
Paris, 75010, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could point toward new ways to prevent or treat graft-versus-host disease without weakening the anti-cancer effect of the transplant.
What could go wrong
This is an observational study, not a treatment trial. It only measures biological markers, so it cannot directly prove any new therapy works. The results may not lead to immediate clinical changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.